Bench-top system helps qualify drug candidates

Desktop Profiler enables therapeutic research laboratories to conduct in-house kinase profiling in a timely and cost-effective manner.

As biotech and pharmaceutical companies continue to explore the potential of kinases as viable drug targets, research scientists increasingly need to understand how drug candidates interact with the hundreds of different kinase enzymes present in the human body.

This kinase profiling is necessary to identifying potential side effects of therapeutic candidates.

Historically, cost constraints have limited the ability of therapeutic laboratories to conduct in-house profiling.

Desktop Profiler provides targeted research laboratories with a simple, affordable system to rapidly profile compounds against a diverse kinase panel.

To ensure ease-of-use, the Desktop Profiler works in conjunction with ProfilerPro kinase panel kits, also launched at SBS.

ProfilerPro microplates are pre-loaded with kinases, substrates and reagents, eliminating assay development and reducing experiment set-up time.

Additionally, the Desktop Profiler utilises Caliper's LabChip microfluidic-based screening technology to yield high-quality, reproducible data that helps researchers more confidently qualify drug candidates.

"The launch of the Desktop Profiler is an important part of our larger strategy to bridge in vitro and in vivo experimentation and enhance the clinical relevancy of drug discovery and development -- for all researchers," said Kevin Hrusovsky, president and CEO of Caliper Life Sciences.

"The Desktop Profiler generates meaningful in vitro data to identify drug candidates that won't drop out during in vivo studies".

The Desktop Profiler and ProfilerPro kinase panel profiling kits will be available in November.

The Desktop Profiler is currently on display at the 12th annual Society for Biomolecular Sciences conference and exhibition in Seattle.